The emergence of novel antibody-based approaches offers fresh optimism that aggressive cancers, such as TNBC, glioma and head and neck carcinomas, which do not benefit from currently available therapies, but for which CSPG4 expression and its tumor-promoting functions have been reported, may become responsive to treatments based on this target. The gene discussed is CSPG4; the disease is glioma.